IRVINE, Calif., Aug. 12, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is happy to announce the intent to seek out 20 – 25 potential candidates suffering from Asthma/COPD and other critical ailments. These initial patients will receive the New MDI Inhalation device FREE for monitoring usage habits, combination levels, and tracking medical results. The observational study is being designed to accumulate valuable data to lead into clinical trials in the State of California.
The CBIS MDI Rescue Inhaler dosage is targeting 100 – 200 dose MDI with cannabinoid level variations ranging from 10mg, 25mg, up to 100mg THC, CBD, and other cannabinoid variables as patient/consumer analysis moves further down the road.
“We are already receiving inquiries from patients looking to be a part of a cannabinoid study targeting several critical ailments so we are responding to the inherent demand from the consumers,” stated CEO Mr. Raymond C. Dabney. “We believe we will get valuable feedback and clinical data from these participants that will aid us in establishing our products as an effective medication for these and other patients that suffer from so many different diseases. We are looking to have these patients in place by the time we launch and distribute this product to our partners and qualified legal vendors. We are very excited about this new product line and its potential to help these diminished lung function patients as well as the many other critical ailments we believe our cannabinoid formulations can help.”
The Cannabis Science Research Foundation will be making the necessary changes to its website to receive the applications from interested patient/participants in this initial trial study. This trial study offer will be limited to the State of California and more specifically the city of Los Angeles.
“Many studies have been done and proven that the Cannabis compounds do indeed aid lung function and Cannabis Science is proud to be the one of the first to offer these types products to the people in the States where it is legal. We believe our new nebulizer medication as well as our CBIS MDI Rescue Inhaler will be a welcome addition to the arsenal of medications for Asthma/COPD suffers and the many other targeted ailments throughout the United States and worldwide,” stated CEO Mr. Raymond C. Dabney.
What is a metered dose inhaler?
A metered dose inhaler is a handheld device that delivers a specific amount of medication in aerosol form, rather than as a pill or capsule. The MDI consists of a pressurized canister inside a plastic case, with a mouthpiece attached. With an MDI, you press on the device while inhaling the COPD medication directly into your lungs. Its portability makes it easy to use anywhere, anytime. MDIs use a chemical propellant to push medication out of the inhaler.
What is a nebulizer?
[neb-u-liz-er] — a device for dispensing liquid in a fine spray; types used include jet and ultrasonic nebulizers. Called also atomizer. Small volume nebulizer a pneumatically powered device used to aerosolize medications for delivery to patients. Ultrasonic nebulizer an electronic device that generates ultrasound waves that break up water into an aerosol mist.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of a unique understanding of biologic processes to provide novel treatment approaches for common ailments and for those disorders where current treatments are relatively unsuccessful and understanding remain incomplete. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the increasingly complex underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3044746
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
Cannabis Science, Inc.
Cannabis Science, Inc.
Mr. Raymond C. Dabney
Director, President & CEO, Co-Founder